Joel A Goldberg

USPTO Granted Patents = 15 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 16.7

ph-index = 6

Forward Citations = 117(Granted Patents)

Location History:

Narberth, PA (US) (2010)
Milford, CT (US) (2005 - 2014)
New Orleans, LA (US) (2016 - 2023)

Company Filing History:

Rib-x Pharmaceuticals, Inc.

patents

2 out of 23

Melinta Therapeutics, Inc.

patents

4. 1 out of 832,680

Other

patents

Years Active: 2005-2025

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12202836 - Bicyclic-fused heteroaryl or aryl compounds (2025-01-21),

2. 11702424 - Bicyclic-fused heteroaryl or aryl compounds (2023-07-18),

3. 10793579 - Bicyclic-fused heteroaryl or aryl compounds (2020-10-06),

4. 10329302 - Bicyclic-fused heteroaryl or aryl compounds (2019-06-25),

5. 9879022 - Bicyclic-fused heteroaryl or aryl compounds (2018-01-30),

6. 9550783 - Biaryl heterocyclic compounds and methods of making and using the same (2017-01-24),

7. 9458168 - Bicyclic-fused heteroaryl or aryl compounds (2016-10-04),

8. 8841263 - Macrocyclic compounds and methods of making and using the same (2014-09-23),

9. 8202843 - Macrocyclic compounds and methods of making and using the same (2012-06-19),

10. 7705026 - Biaryl heterocyclic compounds and methods of making and using the same (2010-04-27),

11. 7456206 - Biaryl heterocyclic compounds and methods of making and using the same (2008-11-25),

12. 7335753 - Bifunctional heterocyclic compounds and methods of making and using same (2008-02-26),

13. 7148219 - Biaryl heterocyclic compounds and methods of making and using the same (2006-12-12),

14. 7091196 - Bifunctional heterocyclic compounds and methods of making and using same (2006-08-15),

15. 6969726 - Biaryl heterocyclic compounds and methods of making and using the same (2005-11-29),

Title: The Innovative Journey of Joel A. Goldberg

Introduction

Joel A. Goldberg, an esteemed inventor based in Milford, Connecticut, is recognized for his significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 14 patents, he has embarked on an innovative journey that showcases his expertise and creativity in developing novel chemical compounds.

Latest Patents

Among his most recent patents are those focused on bicyclic-fused heteroaryl or aryl compounds. These patents disclose various compounds, tautomers, and pharmaceutically acceptable salts. The compounds are defined by a specific structure elucidated in Formula Ia, which is crucial for their efficacy. Furthermore, these patents encompass corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates, reflecting Goldberg's commitment to advancing medical therapeutics.

Career Highlights

Goldberg's professional career has been marked by his tenure at notable companies such as Rib-X Pharmaceuticals, Inc. and Pfizer Corporation. His work in these prestigious organizations has allowed him to hone his skills as an innovative thinker and a problem-solver, driving forward initiatives that have potential implications for healthcare advancements.

Collaborations

Throughout his career, Joel A. Goldberg has collaborated with several distinguished professionals, including Rongliang Lou and Ashoke Bhattacharjee. These collaborations have contributed to the successful development of his inventions, reinforcing the idea that teamwork and shared expertise are vital in the realm of scientific exploration.

Conclusion

Joel A. Goldberg's inventive spirit and dedication to his field have established him as a key figure in the domain of pharmaceutical inventions. His 14 patents not only highlight his intellectual prowess but also demonstrate his unwavering commitment to creating compounds that can enhance treatment options in medicine. As he continues to innovate, Goldberg remains a beacon of inspiration for current and future inventors alike.

This text is generated by artificial intelligence and may not be accurate.